4:42 PM
 | 
Mar 15, 2013
 |  BC Extra  |  Company News

EC approves ThromboGenics' ocriplasmin

ThromboGenics N.V. (Euronext:THR) said the European Commission approved an MAA for Jetrea ocriplasmin to treat vitreomacular traction, including when associated with a macular hole of 400 um or less in...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >